View our masking and visitation guidelines based on current rates of respiratory illnesses in the community.

Our new building on the hospital campus, Forest B, is open. Families and visitors can park in the new Forest B garage next to Emergency.

Clinical Trial Search block Test

An Open-Label Extension Study to Assess the Long-Term Safety And Efficacy Of Dupilumab In Patients ≥6 Months To <18 Years Of Age With Atopic Dermatitis

R668-AD-1434: OLE Dupilumab

Clinicaltrials.gov ID: NCT02612454

What is the goal of the study?

This is a phase 3, open-label extension study investigating the long-term safety, efficacy, PK, and immunogenicity of repeat monthly SC doses of dupilumab in pediatric patients with AD who have previously completed a clinical study with dupilumab in patients with AD. Site For R668-AD-1434: OLE Dupilumab

Who can participate in the study?

Everyone

Study Team:

PI (Study Doctor): Markus Boos
Study Team Member: Jacqueline Lee-Eng, jacqueline.lee-eng@seattlechildrens.org